Tag: Galmed Pharmaceuticals

  • Healthcare New Lows: Ventrus Biosciences (NASDAQ:VTUS), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Galmed Pharmaceuticals (NASDAQ:GLMD), Concert Pharmaceuticals (NYSE:CNCE)

    Ventrus Biosciences Inc (NASDAQ:VTUS) announced top line efficacy and safety results from the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF). In this randomized double blind trial comparing diltiazem 2% cream versus placebo cream in 434 subjects in 90 centers globally, both treatment arms demonstrated a clinically meaningful improvement. Ventrus Biosciences Inc (NASDAQ:VTUS) shares after opening at $1.40 moved to $1.42 on last trade day and at the end of the day closed at $1.33. Company price to cash ratio in past twelve months was calculated as 0.82. Ventrus Biosciences Inc (NASDAQ:VTUS) showed a positive/negative weekly performance of -4.32%.

    TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) J. Kevin Buchi, President and Chief Executive Officer, presented at the Cowen and Company 34th Annual Health Care Conference . Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) shares fell -5.07% in last trading session and ended the day on $6.18. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) return on equity ratio is recorded as 67.10% and its return on assets is -892.00%.

    Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) which is developing an oral treatment for liver diseases, raised $44 million this month. Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) shares moved down -3.73% in last trading session and was closed at $11.10 while trading in range of $11.05-$11.79 – Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) year to date (YTD) performance is -22.43%.

    Research analysts at Roth Capital initiated coverage on shares of Concert Pharmaceuticals (NASDAQ:CNCE) in a report released on Wednesday, AmericanBankingNews.com reports. The firm set a “buy” rating and a $28.00 price target on the stock. Concert Pharmaceuticals, Inc. (NYSE:CNCE) weekly performance is -16.02%. On last trading day company shares ended up $11.69. Concert Pharmaceuticals, Inc. (NYSE:CNCE) distance from 50-day simple moving average (SMA50) is -18.48%. Analysts mean target price for the company is $26.50.